Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Rheumatoid Arthritis

  Free Subscription


03.12.2018

1 Arthritis Res Ther
33 Clin Exp Rheumatol
1 PLoS One
1 Rheumatol Int
1 Scand J Rheumatol
3 Z Rheumatol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Arthritis Res Ther

  1. LOFGREN M, Opava CH, Demmelmaier I, Friden C, et al
    Long-term, health-enhancing physical activity is associated with reduction of pain but not pain sensitivity or improved exercise-induced hypoalgesia in persons with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:262.
    PubMed     Text format     Abstract available


    Clin Exp Rheumatol

  2. KROESE FGM, Haacke EA, Bombardieri M
    The role of salivary gland histopathology in primary Sjogren's syndrome: promises and pitfalls.
    Clin Exp Rheumatol. 2018;36 Suppl 112:222-233.
    PubMed     Text format     Abstract available

  3. LU C, Wu X, Wen H, Gao H, et al
    Primary myelofibrosis but not autoimmune myelofibrosis accompanied by Sjogren's syndrome and primary biliary cirrhosis in a patient with trisomy 8 mosaic: a case report and literature review.
    Clin Exp Rheumatol. 2018;36 Suppl 112:234-236.
    PubMed     Text format     Abstract available

  4. HERNANDEZ-MOLINA G, Valim V, Secco A, Atisha-Fregoso Y, et al
    Do antimalarials protect against damage accrual in primary Sjogren's syndrome? Results from a Latin-American retrospective cohort.
    Clin Exp Rheumatol. 2018;36 Suppl 112:182-185.
    PubMed     Text format     Abstract available

  5. LEE KA, Lee SH, Kim HR
    Diagnostic and predictive evaluation using salivary gland ultrasonography in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:165-172.
    PubMed     Text format     Abstract available

  6. NAKAMURA H, Hasegawa H, Sasaki D, Takatani A, et al
    Detection of human T lymphotropic virus type-I bZIP factor and tax in the salivary glands of Sjogren's syndrome patients.
    Clin Exp Rheumatol. 2018;36 Suppl 112:51-60.
    PubMed     Text format     Abstract available

  7. YONG WC, Sanguankeo A, Upala S
    Association between primary Sjogren's syndrome, cardiovascular and cerebrovascular disease: a systematic review and meta-analysis.
    Clin Exp Rheumatol. 2018;36 Suppl 112:190-197.
    PubMed     Text format     Abstract available

  8. RANTA N, Valli A, Gronholm A, Silvennoinen O, et al
    Proprotein convertase enzyme FURIN is upregulated in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:47-50.
    PubMed     Text format     Abstract available

  9. MOON JS, Shin SY
    Superior oblique myositis causing acquired Brown's syndrome as the first manifestation of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:237-238.
    PubMed     Text format    

  10. AKIYAMA M, Sasaki T, Kaneko Y, Yasuoka H, et al
    Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjogren's syndrome adults from a defined population.
    Clin Exp Rheumatol. 2018;36 Suppl 112:157-164.
    PubMed     Text format     Abstract available

  11. SROKA M, Bagavant H, Biswas I, Ballard A, et al
    Immune response against the coiled coil domain of Sjogren's syndrome associated autoantigen Ro52 induces salivary gland dysfunction.
    Clin Exp Rheumatol. 2018;36 Suppl 112:41-46.
    PubMed     Text format     Abstract available

  12. KARAGEORGAS T, Ioakeimidis D, Mavragani CP
    Psychological comorbidities associated with subclinical atherosclerosis in Greek patients with primary Sjogren's syndrome: a potential contribution of sleep impairment.
    Clin Exp Rheumatol. 2018;36 Suppl 112:68-72.
    PubMed     Text format     Abstract available

  13. LEEHAN KM, Pezant NP, Rasmussen A, Grundahl K, et al
    Minor salivary gland fibrosis in Sjogren's syndrome is elevated, associated with focus score and not solely a consequence of aging.
    Clin Exp Rheumatol. 2018;36 Suppl 112:80-88.
    PubMed     Text format     Abstract available

  14. ALUNNO A, Bistoni O, Carubbi F, Valentini V, et al
    Prevalence and significance of anti-saccharomyces cerevisiae antibodies in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:73-79.
    PubMed     Text format     Abstract available

  15. TORRES-RUIZ J, Faz-Munoz D, Hernandez-Diaz N, Hernandez-Molina G, et al
    Use and withdrawal of immunosuppressors in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:177-181.
    PubMed     Text format     Abstract available

  16. HA YJ, Choi YS, Kang EH, Chung JH, et al
    Increased expression of interferon-lambda in minor salivary glands of patients with primary Sjogren's syndrome and its synergic effect with interferon-alpha on salivary gland epithelial cells.
    Clin Exp Rheumatol. 2018;36 Suppl 112:31-40.
    PubMed     Text format     Abstract available

  17. KAMPOLIS CF, Fragkioudaki S, Mavragani CP, Zormpala A, et al
    Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:94-101.
    PubMed     Text format     Abstract available

  18. MOUTSOPOULOS HM, Skopouli FN
    Sjogren's syndrome: disease activity indexes! Do they make us better clinicians or technicians?
    Clin Exp Rheumatol. 2018;36 Suppl 112:29-30.
    PubMed     Text format    

  19. BARTOLONI E, Alunno A, Valentini V, Valentini E, et al
    The prevalence and relevance of traditional cardiovascular risk factors in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:113-120.
    PubMed     Text format     Abstract available

  20. BALDINI C, Ferro F, Luciano N, Bombardieri S, et al
    Artificial neural networks help to identify disease subsets and to predict lymphoma in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:137-144.
    PubMed     Text format     Abstract available

  21. DE VITA S, Gandolfo S, Zandonella Callegher S, Zabotti A, et al
    The evaluation of disease activity in Sjogren's syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study.
    Clin Exp Rheumatol. 2018;36 Suppl 112:150-156.
    PubMed     Text format     Abstract available

  22. ARGYROPOULOU OD, Gunti S, Kapsogeorgou EK, Notkins AL, et al
    Decrease in the ratio of polyreactive IgG titers with IgG concentration is associated with long-term complications of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:239-240.
    PubMed     Text format    

  23. FLORES-CHAVEZ A, Kostov B, Solans R, Fraile G, et al
    Severe, life-threatening phenotype of primary Sjogren's syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry).
    Clin Exp Rheumatol. 2018;36 Suppl 112:121-129.
    PubMed     Text format     Abstract available

  24. ALUNNO A, Bartoloni E, Valentini V, La Paglia GMC, et al
    Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:210-214.
    PubMed     Text format     Abstract available

  25. BRITO-ZERON P, Retamozo S, Ramos-Casals M
    Phenotyping Sjogren's syndrome: towards a personalised management of the disease.
    Clin Exp Rheumatol. 2018;36 Suppl 112:198-209.
    PubMed     Text format     Abstract available

  26. DELLI K, Dagal EF, Bootsma H, Vissink A, et al
    Patient-reported change of sensibility and pain after parotid and labial gland biopsy applied for primary Sjogren's syndrome diagnostics: one-year follow-up study.
    Clin Exp Rheumatol. 2018;36 Suppl 112:173-176.
    PubMed     Text format     Abstract available

  27. BALDINI C, Zabotti A, Filipovic N, Vukicevic A, et al
    Imaging in primary Sjogren's syndrome: the 'obsolete and the new'.
    Clin Exp Rheumatol. 2018;36 Suppl 112:215-221.
    PubMed     Text format     Abstract available

  28. BOMBARDIERI M, Baldini C, Alevizos I, Akpek E, et al
    Highlights of the 14th International Symposium in Sjogren's Syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:3-13.
    PubMed     Text format    

  29. NOTARSTEFANO C, Croia C, Pontarini E, Lucchesi D, et al
    A clinical and histopathological analysis of the anti-centromere antibody positive subset of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:145-149.
    PubMed     Text format     Abstract available

  30. BRITO-ZERON P, Acar-Denizli N, Ng WF, Zeher M, et al
    How immunological profile drives clinical phenotype of primary Sjogren's syndrome at diagnosis: analysis of 10,500 patients (Sjogren Big Data Project).
    Clin Exp Rheumatol. 2018;36 Suppl 112:102-112.
    PubMed     Text format     Abstract available

  31. KIM SY, Lee J, Choi YS, Kim JW, et al
    Do I sound dry? Comparative voice analysis of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:130-136.
    PubMed     Text format     Abstract available

  32. CINOKU I, Mavragani CP, Tellis CC, Nezos A, et al
    Autoantibodies to ox-LDL in Sjogren's syndrome: are they atheroprotective?
    Clin Exp Rheumatol. 2018;36 Suppl 112:61-67.
    PubMed     Text format     Abstract available

  33. ARGYROPOULOU OD, Valentini E, Ferro F, Leone MC, et al
    One year in review 2018: Sjogren's syndrome.
    Clin Exp Rheumatol. 2018;36 Suppl 112:14-26.
    PubMed     Text format     Abstract available

  34. TZIOUFAS AG, Goules AV
    Limited efficacy of targeted treatments in Sjogren's syndrome: why?
    Clin Exp Rheumatol. 2018;36 Suppl 112:27-28.
    PubMed     Text format    


    PLoS One

  35. CHIN CY, Hsieh SY, Tseng VS
    eDRAM: Effective early disease risk assessment with matrix factorization on a large-scale medical database: A case study on rheumatoid arthritis.
    PLoS One. 2018;13:e0207579.
    PubMed     Text format     Abstract available


    Rheumatol Int

  36. TORRENTE-SEGARRA V, Fernandez Prada M, Exposito Moliner R, Garrido Punal NP, et al
    How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol.
    Rheumatol Int. 2018 Nov 24. pii: 10.1007/s00296-018-4205.
    PubMed     Text format    


    Scand J Rheumatol

  37. VALLI A, Ranta N, Gronholm A, Silvennoinen O, et al
    Increased expression of the proprotein convertase enzyme FURIN in rheumatoid arthritis.
    Scand J Rheumatol. 2018 Nov 26:1-5. doi: 10.1080/03009742.2018.1520294.
    PubMed     Text format     Abstract available


    Z Rheumatol

  38. BAERWALD C, Manger B, Hueber A
    [Depression as comorbidity of rheumatoid arthritis].
    Z Rheumatol. 2018 Nov 28. pii: 10.1007/s00393-018-0568.
    PubMed     Text format     Abstract available

  39. JACOBS H, Callhoff J, Hoffmann F, Zink A, et al
    [Non-drug treatment of rheumatoid arthritis : An analysis of claims data and a survey of insured persons (Project PROCLAIR)].
    Z Rheumatol. 2018 Nov 26. pii: 10.1007/s00393-018-0567.
    PubMed     Text format     Abstract available

  40. ZHANG Q, Yuan R, Li C, Wei W, et al
    Macrophage depletion with clodronate-containing liposomes affects the incidence and development of rheumatoid arthritis.
    Z Rheumatol. 2018 Nov 26. pii: 10.1007/s00393-018-0563.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: